Benjamin Rayner

Has grant

Senior Scientist

Children's Cancer Institute Australia
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Investigating the role of LOXL2/MAOB/MPO in cardiac ischemia reperfusion injury

Open Date: 2016-12-01

Close Date: 2019-12-01

Grant: Close

DNA traps - a new pathway to atherosclerosis

Open Date: 2016-01-01

Close Date: 2016-12-01

Grant: Close

Investigating the molecular mechanisms of remote pre- and post-conditioning within the setting of cardiac ischemia reperfusion injury

Open Date: 2013-12-01

Close Date: 2015-12-01

Grant: Close

Investigating the role of Egr-1 within the setting of cardiac preconditioning

Open Date: 2012-01-01

Close Date: 2012-12-01

Grant: Close

Investigating the effects of synthetic antioxidant supplementation on myocardial ischemia reperfusion injury

Open Date: 2005-11-01

Close Date: 2008-01-01

Articles (2)

Aberrant epigenetic regulation is a hallmark of Diffuse Midline Glioma (DMG), an incurable pediatric brain tumor. The H3K27M driver histone mutation leads to transcriptional dysregulation, indicating that targeting the epigenome and transcription may be key therapeutic strategies against this highly aggressive cancer. One such target is the Facilitates Chromatin Transcription (FACT) histone chaperone. We found FACT to be enriched at developmental gene promoters, coinciding with regions of open chromatin and binding motifs of core DMG regulatory transcription factors. Furthermore, FACT interacted and co-localized with the Bromodomain and Extra-Terminal Domain (BET) protein BRD4 at promoters and enhancers, suggesting functional cooperation between FACT and BRD4 in DMG. In vitro , a combinatorial therapeutic approach using the FACT inhibitor CBL0137, coupled with BET inhibition revealed potent and synergistic cytotoxicity across a range of DMG cultures. These results were recapitulated in vivo , significantly extending survival in three independent orthotopic PDX models of DMG. Mechanistically, we show that CBL0137 treatment decreased chromatin accessibility, synergizing with BET inhibition to cause broad transcriptional collapse, silencing several key oncogenes including MYC, PDGFRA , MDM4 and SOX2 , as well as causing alterations to the splicing landscape. Notably, this combination also elicited immune-related effects, including activation of the interferon response and antigen presentation mechanisms in DMG cells and induction of an activated state in macrophages and T cells, as demonstrated in an immunocompetent setting with spatial transcriptomics. Altogether, our data highlights the therapeutic promise of simultaneously targeting FACT and BET proteins in DMG, offering a dual tumor-intrinsic and immune-mediated strategy for combating this devastating pediatric brain tumor.

Year:

2024

Year:

2023

Collaborators (13)

Marcel Dinger

Dean

University of Sydney

AUSTRALIA
View details

Fatima Valdes-Mora

Team Leader

Children's Cancer Institute Australia

AUSTRALIA
View details

David Ziegler

Professor

University of New South Wales

AUSTRALIA
View details

David Lewis Lawrence

Conjoint Lecturer

UNSW Sydney

AUSTRALIA
View details

Maria Tsoli

Senior Scientist

Children's Cancer Institute Australia

AUSTRALIA
View details

Timothy N. Phoenix

Assistant Professor

University of Cincinnati

UNITED STATES
View details

Mark Ledwidge

Research Director

Trinity College Dublin

IRELAND
View details

Lana McClements

Associate Professor

University of Sydney

AUSTRALIA
View details

Holly Holliday

Children's Cancer Institute Australia

AUSTRALIA
View details

Robert Weatheritt

Associate Professor

UNSW Sydney

AUSTRALIA
View details

Chelsea Mayoh

Children's Cancer Institute Australia

AUSTRALIA
View details

Kristine McGrath

Senior Lecturer

University of Sydney

AUSTRALIA
View details

CHI KIN IP

Children's Cancer Institute Australia

AUSTRALIA
View details